| [2022] FWCA 4359 |
| FAIR WORK COMMISSION |
| DECISION |
Fair Work Act 2009
s.185—Enterprise agreement
Probiotec Pharma Pty Ltd T/A Probiotec Pharma Pty Ltd
(AG2022/4881)
Probiotec Pharma Pty Ltd Enterprise Agreement 2022
| Pharmaceutical industry | |
| DEPUTY PRESIDENT O'NEILL | MELBOURNE, 13 DECEMBER 2022 |
Application for approval of the Probiotec Pharma Pty Ltd Enterprise Agreement 2022
Probiotec Pharma Pty Ltd has applied for approval of an enterprise agreement known as the Probiotec Pharma Pty Ltd Enterprise Agreement 2022 (the Agreement). The application was made pursuant to s.185 of the Fair Work Act 2009 (the Act) and is a single enterprise agreement.
The Employer has provided written undertakings. A copy of the undertakings is attached in Annexure A. I am satisfied that the undertakings will not cause financial detriment to any employee covered by the Agreement and that the undertakings will not result in substantial changes to the Agreement. The undertakings are taken to be a term of the Agreement.
Subject to the undertakings referred to above, I am satisfied that each of the requirements of ss.186, 187, 188 and 190 as are relevant to this application for approval have been met.
The United Workers’ Union being a bargaining representative for the Agreement, has given notice under s.183 of the Act that it wants the Agreement to cover it. In accordance with s.201(2) I note that the Agreement covers the organisation.
I observe that the following provisions are likely to be inconsistent with the National Employment Standards (NES):
· Clause 11.2(b) – Notice of termination by an Employee; and
· Clause 14 – Abandonment of Employment.
However, noting the undertakings given by the Employer, I am satisfied the more beneficial entitlements of the NES will prevail where there is an inconsistency between the Agreement and the NES.
The Agreement is approved and, in accordance with s.54 of the Act, will operate from 20 December 2022. The nominal expiry date of the Agreement is 30 June 2026.
DEPUTY PRESIDENT
Printed by authority of the Commonwealth Government Printer
<AE518520 PR748794>
Annexure A
- AGLC
- Probiotec Pharma Pty Ltd T/A Probiotec Pharma Pty Ltd [2022] FWCA 4359
- Case
- [2022] FWCA 4359
- Decision Date
CaseChat Overview and Summary
The primary legal issues the Commission had to address were whether the proposed agreement met the Fair Work Act's criteria for approval, particularly concerning its compliance with the "better off overall test" and whether it contained any unfair provisions that would result in employees being worse off. The Commission also needed to ensure the agreement was made in good faith and did not unfairly discriminate against or exclude employees.
The Commission found that the proposed agreement was consistent with the Fair Work Act. It was concluded that the agreement was made in good faith and did not include any unfair provisions. The terms of the agreement were deemed to be better for the employees than the applicable award or other relevant industrial instrument. The Commission also noted that the agreement contained provisions that ensured employees would not be subjected to unfair detriment. Consequently, the application for approval was successful.
The Commission approved the Probiotec Pharma Pty Ltd Enterprise Agreement 2022, effective from 1st June 2022. The approval was subject to the terms and conditions specified in the agreement, which would now govern the employment relationship between Probiotec Pharma Pty Ltd and the covered employees.
Orders
Orders of the court
Full text does not contain this section.
Background
Background to the litigation
Full text does not contain this section.
Evidence
Evidence Before The Court
Full text does not contain this section.
Decision
Reasons for decision
Full text does not contain this section.
Ratio Decidendi
Legal Principle Established
Full text does not contain this section.